State-of-the-art: Immunosuppression and biologic therapy

Digestive Diseases

Volumn 28, Issue 3, 2010, Pages 536-542

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

6 Mercaptopurine; Adalimumab; Azathioprine; Certolizumab pegol; Crohn's disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB;

ALLERGIC REACTION; BONE MARROW DEPRESSION; CANCER RISK; CONFERENCE PAPER; CROHN DISEASE; DRUG EFFICACY; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; PANCREATITIS; PRIORITY JOURNAL; TREATMENT RESPONSE; ULCERATIVE COLITIS;

BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957871435     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320413     Document Type: Conference Paper

References (39)

1. Chan GL, Erdmann GR, Gruber SA, Ma-tas AJ, Canafax DM: Azathioprine metabolism: pharmacokinetics of 6-mercaptopu-rine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30: 358-363.
2. Otterness D, Szumlanski C, Lennard L, K lemetsdal B , Aa rbakke J, Park-Hah JO, Iven H, Schmiegelow K, Branum E, O'Brien J, Weinshilboum R: Human thiopurine meth-yltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
3. Colombel JF, Ferrari N, Debuysere H, Mar-teau P, Gendre JP, Bonaz B, Soule JC, Modi-gliani R, Touze Y, Catala P, Libersa C, Broly F: Genotypic analysis of thiopurine S-meth-yltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025-1030.
4. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD: Association of 6-thioguanine nu-cleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterol-ogy 2006; 130 :1047-1053.
5. Dubinsky MC, Yang H, Hassard PV, Seid-man EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915.
6. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroen-terology 1979; 77:847-869.
7. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678.
8. Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995; 123: 132-142 .
9. Cosnes J, Nion-Larmurier I, Beaugerie L, Af-chain P, Tiret E, Gendre JP: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241. Erratum in Gut 2005; 54:734.
10. Leung Y, Panaccione R, Hemmelgarn B, Jones J: Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcer-ative colit is. Dig Dis Sci 2008; 53: 1455-1461.
11. Present DH, Meltzer SJ, Krumholz MP, Wol-ke A, Korelitz BI: 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989; 111:641-649.
12. Kandiel A, Fraser AG, Korelitz BI, Brensin-ger C, Lewis JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercapto-purine. Gut 2005; 54:1121-1125.
13. Beaugerie L, Brousse N, Bouvier AM, Co-lombel JF, Lemann M, Cosnes J, Hebuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadie M, Hermine O, Faivre J, Carrat F: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohor t study. Lancet 2009; 374: 1617-1625.
14. Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ: Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathio-prine or 6-mercaptopurine. Gastroenterol-ogy 2002; 122:72-77.
15. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF: Effi-cac y and safet y of a nti-tumor necrosis factor agents in Crohn's disease: a meta-analysis of placebo-controlled trials. Clin Gastroen-terol Hepatol 2008; 6:644-653.
16. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, De-Woody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
17. Hanauer SB, Sandborn WJ, Rutgeerts P, Fe-dorak RN, Lukas M, MacIntosh D, Panac-cione R, Wolf D, Pollack P: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterolog y 2006; 130: 323-333.
18. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A; for the CCsDSG: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807-818.
19. Sandborn WJ, Feagan BG, Stoinov S, Honi-ball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
20. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rach-milewitz D, Wolf DC, Olson A, Bao W, Rut-geer ts P: Maintenance inf li ximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
21. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schrei-ber S, Byczkowski D, Li J, Kent JD, Pollack PF: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastro-enterology 20 07; 132: 56-65.
22. Schreiber s, Khaliq-Kareemi M, Lawrance I, Ostergaard Thomsen O, Hanauer SB, McC ol m J, Bloom f ie ld R , Sa nd b or n W J: C er-tolizumab pegol maintenance therapy for Crohn's disease. N Engl J Med 2007; 357: 239-250.
23. Sandborn WJ: Clinical perspectives in Crohn's disease: moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord 2007; 7(suppl 2):S23-S35.
24. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Lof-tus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P: Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;136: 1493-1499.
25. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rach-milewitz D, Wolf DC, Olson A, Bao W, Hanauer SB: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126:402-413.
26. Rutgeerts P, Sandborn WJ, Feagan BG, Rei-nisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Present D, Sands BE, Colombel JF: Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
27. Sandborn WJ, Rutgeerts P, Feagan BG, Rei-nisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Co-lombel JF: Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-1260, quiz 1520.
28. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:542-553.
29. Sandborn WJ, Hanauer SB, Rutgeerts P, Fe-dorak RN, Lukas M, MacIntosh DG, Pa-naccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF: Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II tria l. Gut 2007; 56: 1232-1239.
30. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P: Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125:32-39.
31. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analy-sis. Clin Gastroenterol Hepatol 2009; 7:874-881.
32. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-267.
33. Keane J, Gershon S, Wise RP, Mirabile-Lev-ens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
34. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46:2565-2570.
35. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-2869.
36. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos D, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop F, Coche JCR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rut-geerts P, Feagan BG, Hommes D: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667.
37. Lemann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF: Groupe d'Etude Thérapeu-tique des Affections Inf lammatoires du Tube Digestif (GETAID): Inf liximab plus azathio-prine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061.
38. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395.
39. Toruner M, Loftus EV, Colombel JF, Oren-stein R, Harmsen WS, Zinsmeister AR, Sandborn WJ, Egan LJ: Risk factors for opportunistic infections in inf lammatory bowel diseases: a case-control study. Gastroen-terology 2008; 134: 929-936.